Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination

Micro-Cap Stock Rises

After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.

Bacteria
4D Pharma's 'live biotherapeutic' aims to activate a patient's immune system and enable a response to checkpoint inhibitor Keytruda

The results from 4D Pharma Plc's Phase I/II open-label trial of “live biotherapeutics” candidate MRx0518 in combination with Merck & Co., Inc.’s blockbuster Keytruda (pembrolizumab), suggest it could help refractory patients respond to cancer immunotherapy once again.

The Leeds, UK-based micro-cap company has been developing live bacteria therapies to treat a range of immune-related diseases (including irritable...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D